Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin

Figure 5

AgNPs synergize with cisplatin and show favorable dose reduction. (a) A2780, (b) OVCAR3, and (c) SKOV3 cells were treated with AgNP and cisplatin (CDDP) alone or in combination at constant ratios based on IC₅₀ (AgNP (μg/ml) : CDDP (μM), 7.9 : 3.1 for A2780; 322.3 : 5.1 for OVCAR3; and 5.7 : 8.6 for SKOV3) for 72 hours in normal growth medium. Cell viability was assessed by MTT assay and is shown as percent viability relative to vehicle ± standard deviation for AgNP alone, CDDP alone, and the combination of AgNP and CDDP. Additive isoboles () are shown for (d) A2780, (e) OVCAR3, and (f) SKOV3. Plots indicating the combinatorial index for AgNP and CDDP are shown for (g) A2780, (h) OVCAR3, and (i) SKOV3. Dose reduction index is also shown for (j) A2780, (k) OVCAR3, and (l) SKOV3. Synergy analysis (including combinatorial index and dose reduction index) was calculated using CompuSyn software.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)